- Home
- MRUS
MRUS
Merus N.V.
as 11-15-2024 4:00pm EST
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.
| Founded: | 2003 | Country: | Netherlands |
| Employees: | N/A | City: | 3584 CM UTRECHT |
| Market Cap: | 3.6B | IPO Year: | 2016 |
| Target Price: | $86.70 | AVG Volume (30 days): | 376.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.98 | EPS Growth: | N/A |
| 52 Week Low/High: | $22.26 - $61.61 | Next Earning Date: | 10-31-2024 |
| Revenue: | $35,932,000 | Revenue Growth: | -21.33% |
| Revenue Growth (this year): | -16.7% | Revenue Growth (next year): | 52.49% |
Stock Insider Trading Activity of Merus N.V. (MRUS)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Shuman Harry | MRUS | VP Controller, PAO | Aug 20 '24 | Sell | $54.00 | 5,000 | $270,000.00 | 7,002 |
Latest Merus N.V. News
MRUS Breaking Stock News: Dive into MRUS Ticker-Specific Updates for Smart Investing
GuruFocus.com
3 days ago
PDS Biotechnology Corp (PDSB) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges ...
Insider Monkey
4 days ago
Is Merus N.V. (MRUS) Top Performing European Stock Heading into 2025?
GlobeNewswire
11 days ago
Merus to Present at Upcoming Investor Conferences
MT Newswires
12 days ago
Merus Gets FDA Extension on Prescription Drug User Fee Act Goal Date for Zenocutuzumab to Feb. 4
GlobeNewswire
12 days ago
Merus Receives FDA extension of PDUFA for zenocutuzumab
Simply Wall St.
15 days ago
Merus Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
MT Newswires
17 days ago
Merus's Shares Dip After Reporting Wider-Than-Expected Q3 Net Loss
Zacks
17 days ago
Merus N.V. (MRUS) Reports Q3 Loss, Tops Revenue Estimates
Compare MRUS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MRUS Merus N.V. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.